The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 29, 2018

Filed:

Jun. 03, 2011
Applicants:

Bret Berner, Half Moon Bay, CA (US);

Jenny Louie-helm, Fremont, CA (US);

John W. Shell, Hillsborough, CA (US);

Barbara Shell, Hillsborough, CA (US);

Inventors:

Bret Berner, Half Moon Bay, CA (US);

Jenny Louie-Helm, Fremont, CA (US);

John W. Shell, Hillsborough, CA (US);

Assignee:

Depomed, Inc., Newark, CA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 9/20 (2006.01); A61K 31/197 (2006.01); A61K 9/00 (2006.01); A61K 31/00 (2006.01); A61K 31/65 (2006.01); A61K 31/195 (2006.01); A61K 31/496 (2006.01);
U.S. Cl.
CPC ...
A61K 9/0065 (2013.01); A61K 9/20 (2013.01); A61K 31/00 (2013.01); A61K 31/195 (2013.01); A61K 31/197 (2013.01); A61K 31/496 (2013.01); A61K 31/65 (2013.01); A61K 9/2031 (2013.01);
Abstract

Controlled release oral dosage forms are provided for the continuous, sustained administration of a pharmacologically active agent to the upper gastrointestinal tract of a patient in whom the fed mode as been induced. The majority of the agent is delivered, on an extended release basis, to the stomach, duodenum and upper regions of the small intestine, with drug delivery in the lower gastrointestinal tract and colon substantially restricted. The dosage form comprises a matrix of a biocompatible, hydrophilic, erodible polymer with an active agent incorporated therein, wherein the polymer is one that both swells in the presence of water and gradually erodes over a time period of hours, with swelling and erosion commencing upon contact with gastric fluid, and drug release rate primarily controlled by erosion rate.


Find Patent Forward Citations

Loading…